Thomas F. White
Geen lopende functies
Profiel
Thomas F.
White was the founder of BiPar Sciences, Inc. which was founded in 2002, where he held the title of President & Chief Executive Officer.
He also held former positions as Chief Sales & Marketing Officer at Shaman Pharmaceuticals, Inc. and as General Manager & Executive Vice President at Weider Nutrition International, Inc.
Eerdere bekende functies van Thomas F. White
| Bedrijven | Functie | Einde |
|---|---|---|
| Weider Nutrition International, Inc. | Corporate Officer/Principal | - |
Shaman Pharmaceuticals, Inc.
 Shaman Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shaman Pharmaceuticals, Inc. engages in the discovery, development, and marketing of novel, proprietary botanical dietary supplements from tropical plant sources. The company was founded by Lisa A. Conte in May 1989 and is headquartered in San Francisco, CA. | Verkoop & Marketing | - |
BiPar Sciences, Inc.
 BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ. | Oprichter | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
BiPar Sciences, Inc.
BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ. | Health Technology |
| Weider Nutrition International, Inc. | Consumer Non-Durables |
Shaman Pharmaceuticals, Inc.
Shaman Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shaman Pharmaceuticals, Inc. engages in the discovery, development, and marketing of novel, proprietary botanical dietary supplements from tropical plant sources. The company was founded by Lisa A. Conte in May 1989 and is headquartered in San Francisco, CA. | Health Technology |
